LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Acquired by State Street Corp

State Street Corp raised its stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 18.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 289,154 shares of the company's stock after purchasing an additional 45,600 shares during the quarter. State Street Corp owned about 1.05% of LENZ Therapeutics worth $6,865,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Parkman Healthcare Partners LLC acquired a new stake in LENZ Therapeutics during the 3rd quarter valued at $3,308,000. The Manufacturers Life Insurance Company acquired a new stake in shares of LENZ Therapeutics during the third quarter valued at about $743,000. Bank of New York Mellon Corp increased its position in shares of LENZ Therapeutics by 255.4% during the second quarter. Bank of New York Mellon Corp now owns 39,737 shares of the company's stock worth $687,000 after acquiring an additional 28,556 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of LENZ Therapeutics by 197.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 123,371 shares of the company's stock worth $2,929,000 after acquiring an additional 81,901 shares during the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of LENZ Therapeutics in the second quarter worth about $390,000. Hedge funds and other institutional investors own 54.32% of the company's stock.

Analyst Ratings Changes

Several research firms have issued reports on LENZ. William Blair upgraded LENZ Therapeutics to a "strong-buy" rating in a report on Friday, August 30th. HC Wainwright restated a "buy" rating and issued a $38.00 price target on shares of LENZ Therapeutics in a research note on Thursday, November 7th. Finally, Raymond James initiated coverage on shares of LENZ Therapeutics in a research note on Friday, September 27th. They set an "outperform" rating and a $37.00 price objective on the stock. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $35.40.

LENZ Therapeutics Stock Performance

LENZ traded down $0.69 during trading hours on Friday, hitting $31.32. 141,214 shares of the stock were exchanged, compared to its average volume of 138,294. LENZ Therapeutics, Inc. has a 12 month low of $14.42 and a 12 month high of $38.93. The stock has a 50-day simple moving average of $32.25 and a 200-day simple moving average of $25.58.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.09. During the same quarter last year, the business earned ($1.33) earnings per share. Equities research analysts forecast that LENZ Therapeutics, Inc. will post -2.09 EPS for the current year.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.